TradeOrgs
  • 🇮🇳 India
  • 🇺🇸 US
  • Screener
  • Backtest
  • Watchlist
  • Signals
  • Portfolio
  • Insights
  • Connect
Sign in
RELIANCE₹1,377.50▲ 14.60%TCS₹2,376.20▼ 3.44%HDFCBANK₹846.00▲ 18.82%ICICIBANK₹1,640.00▲ 18.75%INFY₹1,098.00▼ 2.89%HINDUNILVR₹2,052.50▲ 10.75%ITC₹299.10▲ 14.69%SBIN₹1,165.10▲ 19.66%BHARTIARTL₹2,161.70▲ 15.28%KOTAKBANK₹515.80▲ 16.62%LT₹4,209.10▲ 14.94%AXISBANK₹1,446.00▲ 16.99%ASIANPAINT₹2,608.30▲ 11.91%MARUTI₹14,011.00▲ 22.10%AAPL$342.56▲ 0.90%MSFT$484.52▼ 8.90%GOOGL$265.29▼ 22.04%AMZN$246.82▼ 6.02%NVDA$125.53▼ 42.01%META$560.84▼ 19.22%TSLA$345.82▼ 7.46%BRK-B$570.00▲ 5.59%JPM$310.53▼ 7.38%V$401.87▼ 1.16%
RELIANCE₹1,377.50▲ 14.60%TCS₹2,376.20▼ 3.44%HDFCBANK₹846.00▲ 18.82%ICICIBANK₹1,640.00▲ 18.75%INFY₹1,098.00▼ 2.89%HINDUNILVR₹2,052.50▲ 10.75%ITC₹299.10▲ 14.69%SBIN₹1,165.10▲ 19.66%BHARTIARTL₹2,161.70▲ 15.28%KOTAKBANK₹515.80▲ 16.62%LT₹4,209.10▲ 14.94%AXISBANK₹1,446.00▲ 16.99%ASIANPAINT₹2,608.30▲ 11.91%MARUTI₹14,011.00▲ 22.10%AAPL$342.56▲ 0.90%MSFT$484.52▼ 8.90%GOOGL$265.29▼ 22.04%AMZN$246.82▼ 6.02%NVDA$125.53▼ 42.01%META$560.84▼ 19.22%TSLA$345.82▼ 7.46%BRK-B$570.00▲ 5.59%JPM$310.53▼ 7.38%V$401.87▼ 1.16%

TradeOrgs shows market information and analyzes your own trading history. It does not place trades and is not investment advice.

Prices and listings are for information only. We are read-only against your broker account.

Technical signals (RSI, MACD, etc.) are educational readouts of public indicators — not recommendations.

Privacy Policy·© 2026 TradeOrgs

← US stocks

🇺🇸ASND

Ascendis Pharma A/S - Ordinary Share

NASDAQ
$252.73
▲ $18.40 (+7.9%)
Live· just now
delayed feed · not for order timing

Price history · 20-day (cyan) / 50-day (purple) avg

as of 20 Nov 2026
H $282.15L $203.80+5.1%
$282.15$266.48$250.81$235.14$219.47$203.8$252.73
RSI (14)
Intraday · 15-minSell-15RSI 39DowntrendMACD Bullishfor day-trading context — not advice

Technical signal

Buy+25
RSI (14)49
oversold 30overbought 70
Trend
Uptrend
MACD
Bearish
Bollinger
Within bands
vs 20-day
below
vs 50-day
above
vs 200-day
above
Support
$242.51
Resistance
$278.56
  • Price is above its 50-day average (medium-term uptrend).
  • Price is above its 200-day average (long-term uptrend).

Signal backtest · 2026-02-20 → 2026-11-20

Strategy return
-25.7%
Buy & hold
+12.3%
Trades
10
Win rate
20%

$100,000.00 invested would be worth $74,347.31 (-25.7%) · Full backtester →

Hypothetical: go long when the signal turns Buy, exit when it turns Sell. Past indicator behavior is not a prediction — educational only, not advice.

About Ascendis Pharma A/S· Biotechnology

source: yahoo

Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Europe, the United States, and internationally. The company offers SKYTROFA for treating pediatric patients with growth hormone deficiency; and YORVIPATH, a once-daily subcutaneous injection for the treatment of adults with chronic hypoparathyroidism. It is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is based in Hellerup, Denmark.

Sector
Healthcare
Industry
Biotechnology
Employees
1,189
Headquarters
Hellerup, Denmark
ascendispharma.com ↗

Fundamentals

source: yahoo
Market cap
$16.58B
P/E
16.6
P/B
9.8
EPS
$15.21
Div yield
0.0%
Profit margin
72.9%
ROE
132.2%
Debt / Equity
0.30
Beta
—
52-week range
$188.08 – $282.15
52-week low · $188.0869% of rangehigh · $282.15

Fundamental data is informational only — not investment advice.

Recent news

News sentiment:▲ Positive4↑ · 0↓ · 4–
  • Why You Shouldn't Forget This Biotech Despite Sell Signal— Neutral
    Investor's Business Daily · 20 Nov 2026
  • Liberty All-Star® Growth Fund, Inc. October 2026 Monthly Update▲ Positive
    Business Wire · 13 Nov 2026
  • Wedbush Raises Price Target on Ascendis Pharma to $346 From $327, Keeps Outperform Rating▲ Positive
    MT Newswires · 13 Nov 2026
  • Ascendis Pharma (ASND) Could Be 12% Below Fair Value Following Q3 Earnings
  • MACD just crossed bearish (momentum turning down).
  • Educational technical indicators — not investment advice. TradeOrgs does not place trades.

    — Neutral
    Simply Wall St. · 13 Nov 2026
  • Ascendis Pharma (ASND) Stock Looks About Right After An 18% Rise▲ Positive
    Simply Wall St. · 13 Nov 2026
  • Ascendis Pharma AS (ASND) Q3 2026 Earnings Call Highlights: Revenue Surges 89% as YORVIPATH and ...▲ Positive
    GuruFocus.com · 12 Nov 2026
  • Sentiment is a keyword-based read of the headline — a rough signal, not advice.